Sentinel Lymph Node Biopsy in Multifocal and Multicentric Breast Cancer
Author Information
Author(s): Alberta Ferrari, Paolo Dionigi, Francesca Rovera, Luigi Boni, Giorgio Limonta, Silvana Garancini, Diego De Palma, Gianlorenzo Dionigi, Cristiana Vanoli, Mario Diurni, Giulio Carcano, Renzo Dionigi
Primary Institution: University of Insubria, Varese, Italy
Hypothesis
Can sentinel lymph node biopsy (SLNB) be accurately performed in patients with multifocal (MF) and multicentric (MC) breast cancer?
Conclusion
The study demonstrates that SLNB is highly accurate in MF and MC breast cancer, indicating that these conditions should not be contraindications for the procedure.
Supporting Evidence
- SLNB was successful in identifying sentinel lymph nodes in 100% of cases.
- The accuracy of frozen section exam on SLN was 96.8%.
- SLN was positive in 41.9% of patients, with some cases of micrometastasis.
- The false-negative rate was only 7.1%, indicating high reliability of the SLNB technique.
- Both MF and MC tumors showed similar lymphatic drainage patterns to unifocal tumors.
Takeaway
Doctors can safely use a special test called sentinel lymph node biopsy for patients with multiple tumors in the breast, which was previously thought to be too risky.
Methodology
Patients with MF or MC breast cancer were injected with a radioisotope tracer and underwent lymphoscintigraphy to evaluate lymphatic drainage before SLNB.
Potential Biases
Potential bias due to the single-institution study design and the selection criteria for patient enrollment.
Limitations
The study had a small sample size and excluded patients with certain conditions, which may limit the generalizability of the findings.
Participant Demographics
All participants were female, with a mean age of 64.1 years.
Statistical Information
P-Value
0.0001
Confidence Interval
Not provided
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website